2017-03-24,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Egalet Corporation - EGLT
2017-03-24,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed A Complaint To Recover Losses Suffered By Investors In Egalet Corporation
2017-03-23,Egalet Announces Issuance Of New U.S. And International Patents For Guardian™ Technology
2017-03-17,2 Questions From the Biotech Mailbag
2017-03-13,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed A Complaint To Recover Losses Suffered By Investors In Egalet Corporation
2017-03-10,Egalet Makes Friday's Biotech Mailbag
2017-03-08,EGLT SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Egalet Corporation And A Lead Plaintiff Deadline Of March 28, 2017
2017-03-07,Egalet To Present At Several Upcoming Scientific Conferences
2017-03-03,EGLT INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Egalet Corporation And A Lead Plaintiff Deadline Of March 28, 2017
2017-03-03,DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Egalet Corporation To Contact The Firm
2017-02-27,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed A Complaint To Recover Losses Suffered By Investors In Egalet Corporation
2017-02-24,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Egalet Corporation Of Class Action Lawsuit And Upcoming Deadline - EGLT
2017-02-23,Egalet To Host Conference Call And Webcast To Discuss Fourth Quarter And Year-End 2016 Financial Results On March 9, 2017
2017-02-22,EGLT SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Egalet Corporation And A Lead Plaintiff Deadline Of March 28, 2017
2017-02-08,EGLT LOSS NOTICE: Rosen Law Firm Reminds Egalet Corporation Investors Of Important Deadline In Class Action - EGLT
2017-02-08,INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Egalet Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
2017-02-02,Lifshitz & Miller Law Firm Announces Investigation Of Alcobra Ltd., Egalet Corporation, Sanderson Farms, Inc., Surgical Care Affiliates, Inc., State Street Corporation, Tenet Healthcare Corp., Vista Outdoor Inc. And Zagg Inc.
2017-02-01,IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Egalet Corporation And Encourages Investors With Losses To Contact The Firm
2017-01-31,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Egalet Corporation - EGLT
2017-01-30,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against Egalet Corporation (EGLT) & Lead Plaintiff Deadline: March 28, 2017
2017-01-24,First Week of March 17th Options Trading For Egalet (EGLT)
2017-01-18,Egalet Closes Second Tranche Of $80 Million Secured Debt Financing
2017-01-12,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Egalet Corporation
2017-01-12,EGALET NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Egalet Corporation To Contact The Firm
2016-12-20,A Biotech Trio to Like Going Into 2017
2016-12-16,Egalet Announces Positive Top-Line Results From An Intranasal Human Abuse Potential Study Of Egalet-002
2016-12-08,Egalet Corporation Appoints Robert Roche To Board Of Directors
2016-12-06,Egalet Announces Issuance Of New Patent For Egalet-002 And Guardian™ Technology
2016-12-01,Egalet Announces Filing Of Supplemental New Drug Application For OXAYDO® To FDA
2016-11-25,Biotech Hits an Inflection Point
2016-11-17,Egalet Announces OXAYDO® Receives Pharmaceutical Composition Patent Protection Through 2024
2016-10-28,Oversold Conditions For Egalet (EGLT)
2016-10-28,Egalet To Present At Abuse-Deterrent Formulations And Investor Conferences This Fall
2016-10-20,Egalet To Host Conference Call And Webcast To Discuss Third Quarter 2016 Financial Results On November 4, 2016
2016-10-13,Egalet Notified that FDA Will Not Meet PDUFA Goal Date for ARYMO ER
2016-09-27,Editorial Discussing Approaches To Category 1 Testing Of Abuse-Deterrent Formulations Of Opioids Published In Pain Practice
2016-09-22,Egalet Announces Publications In Pain Medicine From ARYMO™ ER Oral And Intranasal Human Abuse Potential Studies
2016-09-19,Egalet Appoints Patrick Shea As Chief Commercial Officer
2016-09-15,Bought Aerie Earlier? Congratulations
2016-09-13,Egalet Stock Sees Short Interest Jump 30%
2016-09-12,Egalet Announces OXAYDO® Demonstrates Bioequivalence At 15 Mg Dose
2016-09-08,Egalet Announces Category 1 Abuse-Deterrent Data Demonstrating OXAYDO® Resists Syringeability
2016-08-31,Egalet Completes $40 Million Secured Debt Financing
2016-08-25,Egalet Announces Scientific Presentations At PAINWeek 2016 Meeting
2016-07-21,4 Small-Cap Biotechs With Big Stories to Tell
2016-07-21,Egalet To Host Conference Call And Webcast On August 4, 2016 To Discuss Second Quarter 2016 Financial Results
2016-07-19,Egalet Announces Issuance Of Two New U.S. Patents For Guardian™ Technology
2016-07-07,Insider Trading Alert - EGLT, FMI And ICLD Traded By Insiders
2016-07-07,Egalet To Present At Cantor Fitzgerald Healthcare Conference
2016-06-28,Egalet Announces FDA Advisory Committee Meeting Will Take Place August 4, 2016 For Lead Abuse-Deterrent Candidate ARYMO™ ER (Morphine Sulfate) Extended-Release Tablets
2016-06-17,Egalet Enters Oversold Territory (EGLT)
2016-06-10,Egalet President And CEO Bob Radie Named EY Entrepreneur Of The Year®
2016-05-23,Egalet Settles Patent Litigations With Purdue Pharma
2016-05-06,Relative Strength Alert For Egalet
2016-05-05,Egalet Announces Scientific Presentations At American Pain Society Meeting
2016-05-04,Egalet To Present At Upcoming Investor Conferences This Spring
2016-04-27,Egalet To Host Conference Call And Webcast To Discuss First Quarter 2016 Financial Results On May 10, 2016
2016-04-21,Egalet Announces Upcoming Opportunities For Community To Dispose Of Prescription Medications
2016-04-07,Insider Trading Alert - CTSH, EGLT And CMC Traded By Insiders
2016-04-06,Insider Trading Alert - PNY, EGLT And MA Traded By Insiders
2016-04-05,Insider Trading Alert - ATOS, EGLT And VRNS Traded By Insiders
2016-03-24,Egalet Announces ALERRT(SM) Study Demonstrated Egalet-002 Required Significantly More Effort To Manipulate Than OxyContin®
2016-03-08,Capella Bioscience Completes Series A Financing Of £11 Million ($15.5 Million) To Progress Antibody Pipeline
2016-02-29,Egalet Announces FDA Acceptance Of New Drug Application For ARYMO™ ER (Morphine Sulfate) Extended-Release Tablets
2016-02-23,Egalet To Host Conference Call And Webcast To Discuss Fourth Quarter 2016 Financial Results On March 8, 2016
2016-02-09,Egalet To Present At BIO CEO & Investor Conference
2016-02-08,Egalet Signs Agreement With Septodont, Inc. To Promote SPRIX® (ketorolac Tromethamine) Nasal Spray To Dentists In United States
2016-02-02,Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches As An Independent Venture Capital Firm And Announces Closing Of A €210m Fund Including GSK And Johnson & Johnson Innovation
2016-01-15,Oversold Conditions For Egalet (EGLT)
2016-01-08,Insider Trading Alert - ADSK, EGLT And CPE Traded By Insiders
2016-01-06,Insider Trading Alert - PLOW, DST And EGLT Traded By Insiders
2015-12-17,Egalet Added To NASDAQ Biotechnology Index
2015-12-15,Egalet Submits New Drug Application To U.S. Food And Drug Administration For ARYMO™ ER (Morphine Sulfate) Extended-Release Tablets
2015-12-14,Egalet Signs Agreement With Teva Pharmaceutical Industries To Commercialize SPRIX® (ketorolac Tromethamine) Nasal Spray In Select Geographies Outside The United States
2015-12-09,Egalet Appoints Leading Experts To Scientific Advisory Board
2015-12-03,Egalet Announces Termination Of Shionogi Collaboration
2015-11-16,Egalet Hires Paul Varki As Senior Vice President And General Counsel
2015-11-12,Egalet Announces Issuance Of U.S. Patent Covering Guardian™ Technology And Its Abuse-Deterrent Product Candidates
2015-10-28,Egalet To Participate In Abuse-Deterrent Formulation And Investor Conferences And Will Co-Host A Category 1 Focus Group Meeting In November
2015-10-22,Egalet is Now Oversold (EGLT)
2015-10-21,Egalet To Host Conference Call And Webcast To Discuss Third Quarter 2015 Financial Results On November 4, 2015
2015-10-05,Insider Trading Alert - LOCK, CYBX And EGLT Traded By Insiders
2015-10-05,Egalet Appoints Mark Strobeck, Ph.D. To Executive Vice President And Chief Operating Officer
2015-09-29,Egalet Provides Commercial Update On SPRIX® Nasal Spray And OXAYDO™ Along With Pipeline Review At Investor Day
2015-09-15,Egalet Announces Investor Day
2015-09-10,Egalet Announces Scientific Data At PAINWeek 2015 Meeting Supports Analgesic Efficacy Of SPRIX® Nasal Spray Versus Commonly Prescribed Oral Combination Opioids In Treatment Of Moderate To Severe Short-Term Pain
2015-09-09,Egalet Announces Commercial Launch Of OXAYDO™, The First And Only Immediate-Release Oxycodone Designed To Discourage Intranasal Abuse, And Launch Of IMPACT-Rx, A Patient Access Initiative
2015-09-01,Egalet Announces Scientific Presentations At PainWeek 2015 Meeting
2015-07-31,Egalet Announces Closing Of Public Offering Of Common Stock And Exercise In Full Of Underwriters' Option To Purchase Additional Shares
2015-07-28,Egalet Announces Pricing Of Public Offering Of Common Stock
2015-07-27,Egalet Announces Proposed Public Offering Of Common Stock
2015-07-23,Egalet To Host Conference Call And Webcast To Discuss Second Quarter 2015 Financial Results On August 6, 2015
2015-07-10,Insider Trading Alert - EGLT, STFC And CVGW Traded By Insiders
2015-07-03,Insider Trading Alert - SFBS, WIFI And EGLT Traded By Insiders
2015-07-01,Egalet To Present At Upcoming Conferences This Summer
2015-06-30,Egalet Announces Top-Line Results From Oral Human Abuse Liability Study Of Egalet-002
2015-06-29,Egalet Announces Positive Top-Line Results From Intranasal Human Abuse Liability Study Of Abuse-Deterrent Morphine, Egalet-001
2015-06-25,Egalet's Abuse-Deterrent, Extended-Release Morphine Demonstrates Bioequivalence At 60 Mg Dose
2015-06-23,Egalet Announces Launch Of Specialty Pharmaceutical Sales Force
2015-05-28,Egalet Category 1 Abuse-Deterrent Studies Demonstrated Strong Abuse-Deterrent Properties Of Egalet-002 Compared To Reformulated OxyContin®
2015-05-26,Egalet To Present At Upcoming Conferences In June
2015-05-19,Egalet Announces Issuance Of U.S. Patents Covering Guardian™ Technology And Product Candidates
2015-05-12,Egalet President And Chief Executive Officer Bob Radie Appointed To Pennsylvania Bio Board Of Directors
2015-05-08,Ratings Changes Today
2015-04-23,Egalet To Host Conference Call And Webcast To Discuss First Quarter 2015 Financial Results On May 7, 2015
2015-04-16,Oversold Conditions For Egalet (EGLT)
2015-04-13,Egalet Appoints Nicholas Nicolaides, Ph.D. And John Osborn To Board Of Directors
2015-04-07,Egalet Announces Closing Of $60 Million Offering Of Convertible Senior Notes Due 2020
2015-04-01,Egalet Announces Proposed $60 Million Offering Of Convertible Senior Notes Due 2020
2015-03-24,Rigontec GmbH Raises €4.8m In A Second Closing Of Its Series A Financing
2015-03-17,Egalet Earns $10 Million Milestone Payment Triggered By Advancement Of Shionogi's Abuse-Deterrent, Extended-Release Hydrocodone, S-718632, Using Egalet's Guardian™ Technology
2015-03-09,Egalet To Release 2014 Fourth Quarter And Year-End Financial Results On March 16, 2015 And To Host Conference Call And Webcast To Discuss Commercial Launch On March 25, 2015
2015-02-02,Egalet To Present At Upcoming Conferences In February
2015-01-26,Egalet (EGLT) Stock Gains Today on Price Target Increase
2015-01-22,Egalet Announces Positive Top-Line Results From Oral Human Abuse Liability Study Of Abuse-Deterrent Morphine, Egalet-001
2015-01-12,ORYZON Appoints Greg Weaver As Global Chief Financial Officer
2015-01-09,Egalet Appoints Deanne F. Melloy As Chief Commercial Officer
2015-01-08,Egalet Acquires/Licenses Two Innovative Approved Pain Products
2014-11-05,Egalet To Present At The Stifel 2014 Healthcare Conference On November 18
2014-10-29,Egalet To Host Conference Call And Webcast To Discuss Third Quarter Financial Results On November 12, 2014
2014-10-17,2 Oversold Stocks Under $10 Ready to Bounce Higher
2014-09-23,Egalet Announces Update On Clinical Development Plan For Abuse-Deterrent Morphine Egalet-001
2014-09-11,Egalet Announces Issuance Of U.S. Patents Covering Guardian(TM) Technology And Product Candidates
2014-09-04,Egalet To Present Data From Abuse-Deterrence Studies At PAINWeek 2014 In Las Vegas
2014-08-18,Egalet Announces Successful End-of-Phase 2 Meeting With The FDA For Egalet-002
2014-08-11,Oversold Conditions For Egalet (EGLT)
2014-08-06,Egalet Announces Topline Results From Bioequivalence Studies Of Abuse-Deterrent Morphine, Egalet-001
2014-07-30,Egalet To Present At The Canaccord Genuity Growth Conference On August 13
2014-07-29,Egalet To Host Conference Call And Webcast To Discuss Second Quarter Financial Results On August 12, 2014
2014-07-28,Egalet Appoints Jeffrey M. Dayno, M.D. As Chief Medical Officer
2014-07-15,Egalet Reports Positive Top-Line Results From Category 1 Abuse Deterrence Studies Demonstrating Egalet-001 Resists Physical And Chemical Manipulation
2006-09-06,Wednesday's Small-Cap Winners & Losers
,
